Epilepsy Ireland is seeking feedback from women with epilepsy who are currently taking the anti-seizure medication, Sodium Valproate (Epilim).
The survey is a repeat of a similar survey that we issued in 2019, aimed at measuring patients’ experience of the risk-reduction measures that have been put in place around the prescribing and dispensing of this medication.
If you are a woman with epilepsy and are taking this medication, we are appealing for a moment of your time to please complete this survey, which should take no longer than 10 minutes. To take part, you must be currently taking Sodium Valproate, living in the Republic of Ireland and be:
- A woman (or girl aged 16 or over) with epilepsy
- A parent/carer of a girl aged under 16 with epilepsy
- A parent/carer of a woman with epilepsy who lacks mental capacity
Every response will be vital to our work in assessing the strength of the current risk-reduction measures, understanding any changes that may have occurred since 2019, and ultimately in ensuring a safer outcome for all women prescribed the drug.
Results will also feed into our ongoing work as part of the Sodium Valproate Stakeholder Group which was established by the Minister for Health in 2022.
If you meet the criteria outlined above, you can take our anonymous survey by clicking the button below.
Thank you in advance for your time in completing this important survey.
If you are a women with epilepsy or parent/carer of a girl living with epilepsy and need information or support on your respective journey’s with the condition, please do not hesitate to contact your local Community Resource Officer. You can find their details by visiting the ‘Our Local Service’ section of our website.
Further Information
- Further information about our colleagues in OACS Ireland can be found by visiting the OACS Ireland website.